Patients with previously untreated sAML were randomly assigned at a one-to-one ratio to cytarabine @ mg/m ( @ ) continuous intravenous ( IV ) infusion once per day on days @ to @ plus either amonafide @ mg/m ( @ ) IV over @ hours on days @ to @ ( A + C arm ) or daunorubicin @ mg/m ( @ ) IV over @ minutes once per day on days @ to @ ( D + C arm ) .